Resistance to immune checkpoint inhibitors remains a major barrier in cancer care, often driven by patients relapsing despite initial responses.
-
Resistance to immune checkpoint inhibitors remains a major barrier in cancer care, often driven by patients relapsing despite initial responses. To understand this dynamic, researchers developed a mathematical model focusing on age-associated senescence in CD8+ T cells, where aging immune cells secrete vascular growth factors that support tum...
-
T #medicine shared this topic
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better đź’—
Register Login